| Name | Lesabelimab |
|---|
| Description | Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor[1][2]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |